<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336882">
  <stage>Registered</stage>
  <submitdate>2/05/2011</submitdate>
  <approvaldate>5/05/2011</approvaldate>
  <actrnumber>ACTRN12611000464965</actrnumber>
  <trial_identification>
    <studytitle>Study of Epratuzumab versus Placebo in subjects with moderate to severe general Systemic Lupus Erythematosus (SLE)</studytitle>
    <scientifictitle>A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosus subjects with moderate to severe disease (EMBODY 1)</scientifictitle>
    <utrn />
    <trialacronym>EMBODY 1</trialacronym>
    <secondaryid>NCT01262365  ClinicalTrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Systemic Lupus Erythematosus</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1  Epratuzumab 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
Arm 2  Epratuzumab 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
Arm 3  Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles</interventions>
    <comparator>Placebo infusion - 0.04M PBS with 0.02% polysorbate 80, pH 7.4</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The percent of subjects meeting treatment response criteria at Week 48 according to a combined response index which incorporates criteria for achievement of responder status from the BILAG, SLEDAI, physician's global assessment of disease activity, and concomitant
medication.</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index which incorporates criteria for achievement of responder status from the BILAG, SLEDAI, physician's global assessment of disease activity, and concomitant
medication.</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index which incorporates criteria for achievement of responder status from the BILAG, SLEDAI, physician's global assessment of disease activity, and concomitant
medication.</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index which incorporates criteria for achievement of responder status from the BILAG, SLEDAI, physician's global assessment of disease activity, and concomitant
medication.</outcome>
      <timepoint>Week 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in daily corticosteroid dose at week 24</outcome>
      <timepoint>Baseline, week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in daily corticosteroid dose at week 48</outcome>
      <timepoint>Baseline, week 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Positive antinuclear antibodies (ANA) at Screening (Visit 1)

Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met

Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG)

Active moderate to severe SLE disease as demonstrated by SLEDAI total score

On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects who are breastfeeding, pregnant, or plan to become pregnant

Subjects with active, severe SLE disease activity which involves the renal system

Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease.

Subjects with the evidence of an immunosuppressive state

Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection

History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma.

Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1).

Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C

Subjects with substance abuse or dependence or other relevant concurrent medical condition

Subjects with history of thromboembolic events within 1 year of screening Visit.

Subjects with significant hematologic abnormalities

Subject has received treatment with other anti- B cell antibodies within 12 months prior to screening (visit 1)

Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1)

Subject has previously participated in this study or has previously received epratuzumab treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be screened during the screening period for assessment of study selection criteria and must have at least 1 BILAG level A active body/organ, or at least 2 BILAG level B active body/organ systems at Baseline (Visit 1) among the BILAG-defined mucocutaneous, musculoskeletal, or cardio respiratory body systems as determined by the central independent efficacy reader for BILAG data. 
Patients qualifying for the study according to the inclusion and exclusion criteria will be randomised to treatment in a 1:1:1 ratio.</concealment>
    <sequence>The randomization schedule for assigning subjects to a treatment group was based on a permuted-blocks design (i.e. blocked randomization), stratified by region and  baseline disease severity. The randomization schedule was created using a UCB internal software application (SAS-based) designed for creating randomization schedules, and the randomization was generated by UCB employees otherwise not involved in the conduct of the trial. An IVRS/IWRS will be used for assigning eligible subjects to a treatment regimen based on this predetermined randomization schedule .

The randomization will be stratified by the following 2 factors:
1. Region (eg, Eastern Europe, Western Europe, Middle East and India, Far East, North America, Latin America, and the Pacific); and
2. Baseline disease status:
- SLICC/ACR Damage score =0 and &lt;2 BILAG As at Baseline
- SLICC/ACR Damage score &gt;0 or &gt;=2 BILAG As at Baseline (but not both)
- SLICC/ACR Damage score &gt;0 and &gt;=2 BILAG As at Baseline</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>26/01/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1053</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3145</postcode>
    <postcode>3168</postcode>
    <postcode>4558</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Wurttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Lucknow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Democratic People's Republic Of</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pais Vasco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Islas Canarias</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Essex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>South Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>West Yorkshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>East Sussex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Pernambuco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande Do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Bahia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Sonora</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB, Inc</primarysponsorname>
    <primarysponsoraddress>1950 Lake Park Drive, Smyrna GA 30080, USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>UCB, Inc</fundingname>
      <fundingaddress>1950 Lake Park Drive, Smyrna GA 30080, USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 3, multicenter, placebo-controlled, randomized, double-blind study to evaluate the efficacy, safety, tolerability, and immunogenicity of epratuzumab in subjects with moderate to severe general systemic lupus erythematosus (SLE).
The study population consists of subjects (&gt;=18 years of age) receiving a stable dose of corticosteroids (5 to 60mg/day prednisone equivalents) for at least 5 days (Â±1 day) prior to Week 0 (Visit 2) and the first dose of study drug. Subjects must have a diagnosis of SLE by the American College of Rheumatology (ACR) revised criteria, such that at least 4 (not including Neurologic Disorder) of the 11 criteria are met (if positive for Neurologic Disorder criteria, a total of 5 of the 11 ACR criteria must be met). In addition, subjects must have British Isles Lupus Assessment Group (BILAG) Index (version 2004) level A disease activity in at least 1 body/organ system, or BILAG level B disease activity in at least 2 body/organ systems at Baseline among the BILAG-defined mucocutaneous, musculoskeletal, or cardiorespiratory body systems, and active moderate to severe SLE disease activity as demonstrated by a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of at least 6. 
Approximately 1053 subjects will be enrolled to randomize 780 subjects in this study. For each subject, the study will last a maximum of 54 weeks and will consist of a Screening Period (1 to 14 days), a double-blind Treatment Period consisting of four 12-week treatment cycles (48 weeks total), and a Safety Follow-Up Visit for subjects not participating in the open-label extension study, SL0012, at 13 weeks from their final dose of study drug, or a maximum of 4 weeks beyond Week 48 (ie, no later than Week 52). Eligible subjects will be randomized in a 1:1:1 ratio as follows:

Epratuzumab 600mg infusions delivered once a week (QW) for a total of 4 weeks  (cumulative dose [CMD] 2400mg) over four 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, and 39)

Epratuzumab 1200mg infusions delivered every other week (QOW) for a total of 4 weeks (CMD 2400mg) over four 12-week treatment cycles (ie, Weeks 0, 2, 12, 14, 24, 26, 36, and38); and placebo (PBO) infusions delivered QOW for a total of 4 weeks over four 12-week treatment cycles (ie, Weeks 1, 3, 13, 15, 25, 27, 37, and 39) 

PBO infusions delivered QW for a total of 4 weeks over four 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, and 39)

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with moderate to severe general SLE despite standard of care treatments (ie, corticosteroids, and potentially antimalarials and immunosuppressants) continued from Baseline.

The secondary objectives of the study are to assess the safety, tolerability, and immunogenicity of epratuzumab, and to assess the steroid-sparing effects of epratuzumab treatment.

The exploratory objectives of the study are to assess the pharmacokinetics (PK) of epratuzumab; the effects of epratuzumab treatment on individual components of the combined response index, fatigue associated with moderate to severe SLE, and the health-related quality of life (HRQoL) and utility benefits of epratuzumab treatment.</summary>
    <trialwebsite>www.embodyprogram.com</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Schulman Associates IRB, Inc</ethicname>
      <ethicaddress>4290 Gelndale-Milford Rd, Cincinnati, Ohio 45242</ethicaddress>
      <ethicapprovaldate>15/10/2010</ethicapprovaldate>
      <hrec>10-5760-0</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Leading Ethics Committee: Prof. Dr. J.-M. Maloteaux</ethicname>
      <ethicaddress>Avenue Hippocrate 55-14, 
Tour Harvey-Niveau 0, 1200 Bruxelles.</ethicaddress>
      <ethicapprovaldate>31/01/2011</ethicapprovaldate>
      <hrec>OM 003</hrec>
      <ethicsubmitdate />
      <ethiccountry>Belgium</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Leading Ethics Committee: CPP  - Ile de France V1</ethicname>
      <ethicaddress>10, Pavilion Jacquard
47, Bd De L'Hopital 
75651 Paris Cedex 13</ethicaddress>
      <ethicapprovaldate>21/01/2011</ethicapprovaldate>
      <hrec>CPP no 112-10</hrec>
      <ethicsubmitdate />
      <ethiccountry>France</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Institute review board of Gangnam Severance Hospital</ethicname>
      <ethicaddress>712 Eonguro Ganman-gu, Seoul, 135-720</ethicaddress>
      <ethicapprovaldate>26/01/2011</ethicapprovaldate>
      <hrec>3-2010-0237</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Democratic People's Republic Of</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Medical Institution's Helsinki Committee to Conduct a Clinical Trial in Human Beings</ethicname>
      <ethicaddress>Helsinki Committee of Bnai Zion Medical Center, Bnai Zion Medical Center, 43 Golomb St.,P.O.Box 4940 Haifa 31048,</ethicaddress>
      <ethicapprovaldate>29/12/2010</ethicapprovaldate>
      <hrec>0143-10-BNZ</hrec>
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Shalby Hospital</ethicname>
      <ethicaddress>Shalby Hospital, Opp. Karnavati Club, S.G. Road, Ahmedabad-380015,Gujarat,</ethicaddress>
      <ethicapprovaldate>9/02/2011</ethicapprovaldate>
      <hrec>NAP</hrec>
      <ethicsubmitdate />
      <ethiccountry>India</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eulji University Hospital IRB</ethicname>
      <ethicaddress>IRB office, Clinical trial center, Eulji University Hospital, 1306, Dunsan-dong, Seo-gu, Daejeon, 302-799</ethicaddress>
      <ethicapprovaldate>9/02/2011</ethicapprovaldate>
      <hrec>11-004</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Democratic People's Republic Of</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>SCMC IRB</ethicname>
      <ethicaddress>IRB office, Room 226, The Catholic University of Korea, Yeouido St. Mary's Hospital, 62 Yeouido-dong, Yeongdeungpo-gu, Seoul, 150-713</ethicaddress>
      <ethicapprovaldate>28/02/2011</ethicapprovaldate>
      <hrec>SIRB-00170-001</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Democratic People's Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jenny Omadoye</name>
      <address>Clinical Project Manager 
UCB BioSciences GmbH
Alfred-Nobel-Str. 10
40789 Monheim</address>
      <phone>+49 (0)2173 48 1024</phone>
      <fax />
      <email>jenny.omadoye@ucb.com</email>
      <country>Germany</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dulce Lauterbach</name>
      <address>PAREXEL International Pty Ltd 
Suite B Level 6, 15 Talavera Road North Ryde NSW 2113</address>
      <phone>+61 2 8870 3100 (reception) +61 2 8870 3191 (direct)</phone>
      <fax />
      <email>dulce.lauterbach@parexel.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Melissa Dunn</name>
      <address>PAREXEL International Pty Ltd
C/O Suite B Level 6, 15 Talavera Road North Ryde NSW 2113</address>
      <phone>+61 8 8288 0544</phone>
      <fax>+61 8 8288 0599</fax>
      <email>melissa.dunn@parexel.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>